Replies to post #238327 on Biotech Values

[DewDiligence]

GILD vs BMY in LBCL CAR-T—who has the edge?

https://www.fiercepharma.com/pharma/bristol-myers-squibb-breyanzi-gilead-yescarta-lock-horns-car-t-therapy-earlier-lymphoma

Both Yescarta and Breyanzi are poised to take share from stemcell transplants.